Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06547528 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary endpoints: details revised at 1 of 14 entries Enrollment closed, study ongoing · Eligibility criteria expanded, about 12 words · Secondary endpoints: details revised at 1 of 17 entries · 1 more Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 1 of 17 entries
    • Site details revised at 14 of 14 sites
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
Trial Details
NCT Number NCT06547528
Lead Sponsor Ono Pharmaceutical Co., Ltd.
Conditions Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment 108 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov